Cambridge University's Personalised Breast Cancer Programme has already identified multiple imperceptible mutations, changing patient treatment for the better. This programme has set a new standard: it was the first group — worldwide — to use Cambridge-developed Next Generation Sequencing as a routine, standard-of-care diagnostic and clinical tool.

These data-led approaches are the key to unlocking better treatments, and we will implement them widely across all cancer types.